Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-14 of 14 for your search:
Drug:
lomustine
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MRC-BR12
, EU-20114, ISRCTN83176944, NCT00052455
2.
Phase III Randomized Adjuvant Study of Standard-Dose Versus Reduced-Dose Craniospinal Radiotherapy and Posterior Fossa Boost Versus Tumor Bed Boost Radiotherapy in Combination With Chemotherapy Comprising Vincristine, Cisplatin, Lomustine, and Cyclophosphamide in Pediatric Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ACNS0331
, ACNS0331, NCT00085735
3.
Phase III Randomized Study of Standard Chemoradiotherapy With Versus Without High-Dose Methotrexate in Pediatric Patients With Newly Diagnosed, Malignant High-Grade Glioma or Diffuse Intrinsic Pontine Glioma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 18
Sponsor:
Other
Protocol IDs:
GPOH-HIT-GBM-D
, EU-205100, NCT00278278
4.
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other
Protocol IDs:
CHUBX 2007/13
, NCT00590837
5.
Phase III: Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
D8480C00055
, NCT00777153
6.
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2004-0595
, NCT00527657
7.
Phase II Study of Adjuvant Reduced-Dose Craniospinal Radiotherapy With Vincristine Followed By Maintenance Chemotherapy in Children With Newly Diagnosed Standard-Risk Posterior Fossa Primitive Neuroectodermal Tumor or Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 to 30 at initial diagnosis
Sponsor:
Other
Protocol IDs:
CHP-693
, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
8.
Phase II Pilot Study of Post-Operative Intrathecal Radioimmunotherapy, Reduced-Dose Craniospinal Radiotherapy With Intensity-Modulated Radiotherapy Boost, and Chemotherapy in Patients With Standard-Risk Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-02088
, NCT00058370
9.
Phase II Study of Hyperfractionated Accelerated Radiotherapy (HART) Followed By Adjuvant Combination Chemotherapy Comprising Lomustine, Cisplatin, and Vincristine in Pediatric Patients With Nonpineal Supratentorial Primitive Neuroectodermal Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 to 18
Sponsor:
Other
Protocol IDs:
CCLG-CNS-2004-01
, EU-20580, NCT00274911
10.
Phase II Study of Adjuvant Hyperfractionated Accelerated Radiotherapy (HART) Followed By Maintenance Chemotherapy Comprising Lomustine, Cisplatin, and Vincristine in Young Patients With Metastatic Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 to 21
Sponsor:
Other
Protocol IDs:
CCLG-CNS-2001-06
, EU-20577, NCT00276666
11.
Second-Line Treatment in Patients With Small Cell Lung Cancer (SCLC)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GFPC 05-01
, NCT00418743
12.
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
Other
Protocol IDs:
2003-0600
, NCT00504660
13.
Multi-Protocol Study of Conventional Reduced-Dose or Hyperfractionated Radiotherapy and Combination Chemotherapy in Pediatric Patients With Intracranial Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
0 to 21
Sponsor:
Other
Protocol IDs:
GPOH-HIT-2000
, EU-205105, NCT00303810
14.
Study of Reinduction Combination Chemotherapy Followed by Allogeneic or Autologous Stem Cell Transplantation in Pediatric Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
Under 22
Sponsor:
Other
Protocol IDs:
EICNHL-ALCL-RELAPSE
, AIEOP-EICNHL-ALCL-RELAPSE, BFM-EICNHL-ALCL-RELAPSE, BSPHO-EICNHL-ALCL-RELAPSE, DCOG-EICNHL-ALCL-RELAPSE, NOPHO-EICNHL-ALCL-RELAPSE, PPLLSG-EICNHL-ALCL-RELAPSE, SFCE-EICNHL-ALCL-RELAPSE, SHOP-EICNHL-ALCL-RELAPSE, CCLG-NHL-2006-01, EU-205118, EU-20618, EUDRACT-2005-003321-57, NCT00317408
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
